These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24368057)

  • 1. Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse.
    Di Cosimo S; Serpico D; Porcu L; Molino L; Fanetti G; Torri V; de Braud F
    Clin Oncol (R Coll Radiol); 2014 Mar; 26(3):174. PubMed ID: 24368057
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 testing in patients with breast cancer.
    Dixon JM; Wilson V; Verrill M; Symmans WF
    BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887
    [No Abstract]   [Full Text] [Related]  

  • 4. Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer.
    Zucchini G; Bernardi A; Martoni A; Zamagni C
    Ann Oncol; 2013 Jan; 24(1):264-5. PubMed ID: 23251010
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant trastuzumab for HER2-positive breast cancer.
    Spicer J; Harries M; Ellis P
    Lancet; 2005 Aug 20-26; 366(9486):634. PubMed ID: 16112298
    [No Abstract]   [Full Text] [Related]  

  • 6. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
    de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
    Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
    Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
    Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
    Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY
    PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical practice-changing trials: the HERA study paradigm.
    Zardavas D; Ades F; de Azambuja E
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1249-56. PubMed ID: 24138446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer.
    Araki K; Saji S; Gallas M; Pegram M; Sasaki Y
    Breast Cancer; 2012 Apr; 19(2):95-103. PubMed ID: 21863310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
    Tuma RS
    J Natl Cancer Inst; 2012 Jul; 104(13):968-9. PubMed ID: 22745473
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant trastuzumab for HER2-positive early breast cancer.
    Palmieri FM; Myatt CV; Perez EA
    Clin J Oncol Nurs; 2010 Jun; 14(3):326-36. PubMed ID: 20529794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Small HER2-positive breast cancer: which prognosis and which adjuvant treatment?].
    Gonçalves A; Vassilakopoulou M; Spano JP
    Bull Cancer; 2013 Sep; 100(9):847-56. PubMed ID: 23899689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 18. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab in small tumours and in elderly women.
    Albanell J; Ciruelos EM; Lluch A; Muñoz M; Rodríguez CA
    Cancer Treat Rev; 2014 Feb; 40(1):41-7. PubMed ID: 23659993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.